Catalyst Pharmaceuticals (NASDAQ:CPRX) Shares Gap Down to $6.13

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) gapped down before the market opened on Friday . The stock had previously closed at $5.55, but opened at $6.13. Catalyst Pharmaceuticals shares last traded at $6.04, with a volume of 291,206 shares.

CPRX has been the topic of several research analyst reports. Cantor Fitzgerald lifted their price objective on shares of Catalyst Pharmaceuticals from $10.00 to $12.00 in a research report on Thursday, August 8th. Zacks Investment Research upgraded shares of Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $5.75 price objective on the stock in a research report on Wednesday, July 31st. BidaskClub upgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 3rd. Finally, SunTrust Banks reiterated a “buy” rating and set a $11.00 price objective (up from $9.00) on shares of Catalyst Pharmaceuticals in a research report on Thursday, August 8th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $8.54.

The firm’s fifty day moving average price is $5.68 and its 200 day moving average price is $4.49. The company has a current ratio of 5.09, a quick ratio of 5.07 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $712.27 million, a PE ratio of -18.82 and a beta of 2.38.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last posted its quarterly earnings results on Wednesday, August 7th. The biopharmaceutical company reported $0.10 EPS for the quarter, beating the consensus estimate of $0.03 by $0.07. The company had revenue of $28.84 million for the quarter, compared to analysts’ expectations of $17.99 million. During the same quarter in the prior year, the firm earned ($0.06) earnings per share. The company’s revenue was up 2883900.0% on a year-over-year basis. As a group, research analysts expect that Catalyst Pharmaceuticals Inc will post 0.34 EPS for the current year.

Institutional investors have recently bought and sold shares of the company. Meeder Asset Management Inc. grew its holdings in shares of Catalyst Pharmaceuticals by 678.1% during the 2nd quarter. Meeder Asset Management Inc. now owns 13,251 shares of the biopharmaceutical company’s stock valued at $50,000 after acquiring an additional 11,548 shares in the last quarter. Bank of Montreal Can grew its holdings in shares of Catalyst Pharmaceuticals by 159.1% during the 2nd quarter. Bank of Montreal Can now owns 12,953 shares of the biopharmaceutical company’s stock valued at $50,000 after acquiring an additional 7,953 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of Catalyst Pharmaceuticals during the 2nd quarter valued at $55,000. Paradigm Capital Management Inc. NY purchased a new position in shares of Catalyst Pharmaceuticals during the 2nd quarter valued at $77,000. Finally, Jefferies Group LLC purchased a new position in shares of Catalyst Pharmaceuticals during the 2nd quarter valued at $77,000. Institutional investors and hedge funds own 59.81% of the company’s stock.

Catalyst Pharmaceuticals Company Profile (NASDAQ:CPRX)

Catalyst Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome in the United States.

Featured Article: 12b-1 Fees

Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.